Last reviewed · How we verify
NCT06156670: ENDOVAL
Russian Registry of Endovascular Closure of PFO
trial testing PFO closure in Patent Foramen Ovale in 700 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | National Medical Research Center for Cardiology, Ministry of Health of Russian Federation |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 700 |
| Start date | 1 December 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- PFO closure
Conditions studied
- Patent Foramen Ovale — all drugs for Patent Foramen Ovale →
Sponsor
National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Who can join
Adults 18 to 70, any sex, with Patent Foramen Ovale. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will include all patients over 18 years of age who underwent endovascular closure of patent foramen ovale in medical centers in the Russian Federation, who gave written informed consent to the closure and provided personal data as part of inpatient medical care. The project participants will be 29 medical centers in the Russian Federation, where endovascular closure of patent foramen ovale is performed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06156670
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PFO closure
Trials testing the same drug.
- NCT07479147 — SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation · recruiting
- NCT06113562 — Close Obstructive Sleep Apnea (OSA) Trial · NA · withdrawn
- NCT06413147 — Long-term Procedural and Device Related Complications of PFO Closure · not yet recruiting
- NCT05238610 — Prospective Registry of Elderly ESUS With PFO · recruiting
- NCT04738071 — International Multicenter Patent foRamen OVale & strokE (IMPROVE) Registry · unknown
Other recruiting trials for Patent Foramen Ovale
Currently open trials in the same condition.
- NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
- NCT05907694 — Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure · NA · recruiting
- NCT06953622 — Establishment of a Clinical and Prognostic Follow-up Cohort of Migraine Patients With Patent Foramen Ovale · recruiting
- NCT05387954 — PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years · Phase 3 · recruiting
- NCT05774288 — Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. · NA · recruiting
Other National Medical Research Center for Cardiology, Ministry of Health of Russian Federation trials
Trials by the same sponsor.
- NCT06655480 — Triple Combination Therapy (ARNI, SGLT2i, MRA) in Advanced HFpEF · Phase 2 · not yet recruiting
- NCT06683001 — National Heart Failure Registry · recruiting
- NCT07452991 — ULTRAsound-assisted Catheter-guided Thrombolysis for Intermediate-high Risk Patients With PE · NA · recruiting
- NCT06540352 — A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term · Phase 2 · active not recruiting
- NCT06683040 — Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension · Phase 2, PHASE3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06156670 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Last refreshed: 29 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06156670.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing